Breast : Adjuvant
Study: BIG2-06
Participation via CTSU
Description: BIG 2-06/N063D, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study - A randomised, multi-centre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Limited Participants: None
Notes:
Breast : Adjuvant
Study: E5103
Participation via CTSU
Description: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Limited Participants: None
Notes:
Breast : Metastatic
Study: 40502
Participation via CTSU
Description: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound (Nab)-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Limited Participants: None
Notes:
Breast : Metastatic
Study: N0733
Description: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive, Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
Limited Participants: None
Notes:
Breast : Metastatic
Study: N0735
Description: Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer
Limited Participants: None
Notes:
| .
| CNS : Brain
Study: 0825
Participation via CTSU
Description: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
Limited Participants: None
Notes:
CNS : Brain
Study: N0272
Description: Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Limited Participants: None
Notes:
CNS : Brain
Study: N0572
Description: A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma
Limited Participants: None
Notes:
CNS : Brain
Study: N0574
Description: A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases
Limited Participants: None
Notes:
CNS : Brain
Study: N0577
Description: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Limited Participants: None
Notes:
CNS : Brain
Study: N057K
Description: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma
Limited Participants: None
Notes:
CNS : Brain
Study: N0776
Description: Phase II Trial of Avastin in Combination with Sorafenib in Recurrent Glioblastoma Multiforme
Limited Participants: None
Notes:
CNS : Brain
Study: N0779
Description: Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme
Limited Participants: None
Notes:
CNS : Brain
Study: N0872
Temporarily Closed
Description: Phase I/II Study of Dasatinib/Bevacizumab in Recurrent Glioblastoma
Limited Participants: MC Florida MC Arizona
Notes:
CNS : Brain
Study: N0874
Temporarily Closed
Description: NCCTG/ABTC phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Limited Participants: MC Florida MC Arizona
Notes:
CNS : Brain
Study: N0877
Temporarily Closed
Description: Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
Limited Participants: MC Florida MC Arizona
Notes:
CNS : Other CNS
Study: N027D
Temporarily Closed
Description: A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme
Limited Participants: MC Florida MC Arizona
Notes:
| .
| GI : Carcinoid
Study: S0518
Participation via CTSU
Description: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Limited Participants: None
Notes:
GI : Colorectal
Study: N0147
Description: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
Limited Participants: None
Notes:
GI : Colorectal
Study: N054C
Temporarily Closed
Description: Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer
Limited Participants: None
Notes:
GI : Esophagus
Study: N0747
Description: A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (with the potential for crossover) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Limited Participants: None
Notes:
GI : Liver
Study: N0745
Description: Phase I/II Randomized Study of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma
Limited Participants: None
Notes:
GI : Pancreas
Study: N064A
Description: Phase II Study of Panitumumab, Chemotherapy and External Beam Radiation in Patients with Locally Advanced Pancreatic Cancer
Limited Participants: None
Notes:
GI : Pancreas
Study: N064B
Description: Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma
Limited Participants: None
Notes:
GI : Sm Bowel
Study: N0543
Description: A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Limited Participants: None
Notes:
| .
| GYN : Ovary
Study: MC0261
Faxed Checklist Only
Description: A Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas
Limited Participants: None
Notes:
| .
| Hematology : Non Hodgkin'
Study: N0682
Description: A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma
Limited Participants: None
Notes:
Hematology : Non Hodgkin'
Study: N078D
Description: Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Limited Participants: None
Notes:
Hematology : Other Hem
Study: E1F05
Faxed Checklist Only
Description: Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
Limited Participants: None
Notes:
Hematology : Other Hem
Study: N078D
Description: Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Limited Participants: None
Notes:
| .
| Lung : Mixed
Study: N0724
Description: A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Systemic Therapy plus Either Radiotherapy to all Sites of Gross Residual Disease or No Radiotherapy
Limited Participants: None
Notes:
Lung : NSCLC
Study: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |